New Delhi: As Covid-19 cases surge in Delhi, and several school children and teachers tested positive in Noida and Ghaziabad, the need for a vaccine for kids has risen. The Subject Expert Committee (SEC) of Drugs Controller General of India (DCGI) has recommended the emergency use of Corbevax Covid vaccine developed by Hyderabad-based Biological E, for children between 5-12 years.
If the DCGI gives a nod to the recommendation, the Union Health Ministry may give final approval for the emergency use of the vaccine.
Corbevax is India’s first indigenously developed protein subunit vaccine against Covid-19. The Receptor Binding Domain (RBD) vaccine uses similar technology to that of hepatitis B vaccines. The vaccine is currently being administered to children between 12-14 years. The vaccine is administered through an intramuscular route with two doses scheduled 28 days apart.
Corbevax For Kids Above 12
In December 2021, an expert panel had recommended the emergency use of Corbevax for adolescents between 12-18 years of age subject to certain conditions. On February 9, Biological E received approval for conducting phase 2/3 clinical study for Corbevax among children and adolescents in this age gap.
Covaxin For Children Aged 2-12 Years
Meanwhile, the Subject Expert Committee of the DCGI has asked Bharat Biotech for additional data of Covaxin being administered to children between 2-12 years of age. This comes after the SEC recommended emergency use of Covaxin for children belonging to this particular age gap. However, no recommendations have been made so far.
Rising Covid Cases Among Children
In view of the recent surge in Covid cases among children, the Delhi government issued an advisory to be followed by schools. Hand sanitisation should be imposed in every corner of the school. School authorities have been asked to ensure physical distancing. Schools have been asked to provide a quarantine room, in case of any emergencies. Penalty will be imposed in case of non-compliance of the SOPs.